Dergiler / Turkish Journal of Chemistry / 2020 / Cilt: 44 - Sayı: 4

In silico ADME predictions and in vitro antibacterial evaluation of 2-hydroxy benzothiazole-based 1,3,4-oxadiazole derivatives

Sayfa
1068–1084
Yayın Tarihi
2020-08-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

It can be concluded that the synthesized compound could be used as a lead molecule in the development of new antibacterial agents with high efficacy.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:In the present work, a library of fifteen 2-hydroxy benzothiazole-linked 1,3,4 -oxadiazole derivatives have been synthesized and confirmed using different analytical techniques.
📊
Temel Bulgular & Veri:From the ADME predictions, compound 4 showed the highest in silico absorption percentage (86.77%), while most of the compounds showed more than 70% absorption.
💡
Sonuç & Katkı:It can be concluded that the synthesized compound could be used as a lead molecule in the development of new antibacterial agents with high efficacy.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Heterocycles · pharmacokinetics · minimum inhibitory concentration

Abstract

In the present work, a library of fifteen 2-hydroxy benzothiazole-linked 1,3,4 -oxadiazole derivatives have been synthesized and confirmed using different analytical techniques. All of the synthesized compounds have been tested for antibacterial and in silico pharmacokinetic studies for the first time. From the ADME predictions, compound 4 showed the highest in silico absorption percentage (86.77%), while most of the compounds showed more than 70% absorption. All of the compounds comply with the Lipinski rule of 5, suggesting that the compounds possess good drug likeness properties upon administration. Furthermore, all of the compounds follow the Veber rule, indicating good bioavailability and good intestinal absorption. The antibacterial results exhibited excellent to moderate activity. Compounds 5, 9, 12, 14, 15, 16, and 17 were the most active compounds against the tested bacterial strains. Compound 14 showed comparable MIC 6.25 +/- 0.2 mu g/disc to the standard drug amoxicillin against the tested Gram-positive bacterial strains. Compounds 5, 14, 17 exhibited MIC 12.5 +/- 0.8 mu g/disc, which was comparable to the standard drug against E. faecalis. It can be concluded that the synthesized compound could be used as a lead molecule in the development of new antibacterial agents with high efficacy.

🔖

Bu Makaleye Atıf Yap

ALGHAMDİ, A. A., ALAM, M. M., NAZREEN, S. (2020). In silico ADME predictions and in vitro antibacterial evaluation of 2-hydroxy benzothiazole-based 1,3,4-oxadiazole derivatives. Turkish Journal of Chemistry, Cilt: 44 - Sayı: 4, 1068–1084. https://ajindex.com/articles/214928

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Al Ghamdi HAH, 2020, INDIAN J HETEROCY CH, V30, P55 Alghamdi AA, 2020, EGYPT J CHEM, V63, P471, DOI 10.21608/ejchem.2019.17265.2059 Alzhrani ZMM, 2020, J ENZYM INHIB MED CH, V35, P1116, DOI 10.1080/14756366.2020.1759581 Azam F, 2012, J YOUNG PHARM, V4, P184, DOI 10.4103/0975-1483.100027 Delmas F, 2004, EUR J MED CHEM, V39, P685, DOI 10.1016/j.ejmech.2004.04.006 Hanumanagoud H, 2013, PHARM CHEM, V5, P8798 Huang ST, 2006, BIOORGAN MED CHEM, V14, P6106, DOI 10.1016/j.bmc.2006.05.007 Iqbal AKM, 2012, EUR J MED CHEM, V53, P308, DOI 10.1016/j.ejmech.2012.04.015 Joshi SD, 2008, EUR J MED CHEM, V43, P1989, DOI 10.1016/j.ejmech.2007.11.016 Kamal A, 2015, EXPERT OPIN THER PAT, V25, P335, DOI 10.1517/13543776.2014.999764 Kamal A, 2013, BIOORG MED CHEM LETT, V23, P6842, DOI 10.1016/j.bmcl.2013.10.010 Koci J, 2002, BIOORG MED CHEM LETT, V12, P3275 Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1 Munirajasekhar D, 2014, J HETEROCYCLIC CHEM, V51, P459, DOI 10.1002/jhet.1618 Nagarajan SR, 2003, BIOORGAN MED CHEM, V11, P4769, DOI 10.1016/j.bmc.2003.07.001 Neervannan S, 2006, EXPERT OPIN DRUG MET, V2, P715, DOI 10.1517/17425255.2.5.715 Patel Navin B, 2010, Saudi Pharm J, V18, P129, DOI 10.1016/j.jsps.2010.05.002 Patel RV, 2015, RES CHEM INTERMEDIAT, V41, P5599, DOI 10.1007/s11164-014-1684-8 Shepard DR, 2010, EXPERT OPIN INV DRUG, V19, P899, DOI 10.1517/13543784.2010.491822 Siddiqui N, 2009, J ENZYM INHIB MED CH, V24, P1344, DOI 10.3109/14756360902888176 Takasu K, 2002, J MED CHEM, V45, P995, DOI 10.1021/jm0155704 UPMANYU N, 2012, DHAKA U J PHARM SCI, V11, P7 Van Zandt MC, 2005, J MED CHEM, V48, P3141, DOI 10.1021/jm0492094 Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n Yogeeswari P., 2005, Farmaco (Lausanne), V60, P1, DOI 10.1016/j.farmac.2004.09.001